However, assessment of EGFR expression can be affected by immunoreactivity of normal tissues, differential EGFR reactivity of neoplasms from different areas of the bowel, and heterogeneity of reactivity within the colorectal carcinoma itself [17], [37]. This evidence concerns the gene EGFR and neoplasm.